Seeking Alpha

Novartis net profit falls 3.1%; raises FY outlook

  • Novartis (NVS) Q3 core net income -3.1% to $3.1B, almost in line with consensus of $3.12B.
  • Core EPS $1.26, below forecasts of $1.29.
  • Sales +4% to $14.3B, in line.
  • Raises annual forecasts for second time this year and now expects sales to increase at a low- to mid-single-digit percentage rate in constant currencies, and core operating income to match or grow from last year. The reason for the increase is because India's Ranbaxy Laboratories hasn't yet started selling a generic version of Novartis' Diovan blood-pressure drug in the U.S. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: